Philadelphia, PA, Jan. 21, 2016 – Numerous genetic variants associated with risk for schizophrenia have been identified. However, little is known about how these genes have their effects in the brain.
A proof-of-concept study published in the inaugural issue of the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging proposes a computer model for measuring the cumulative impact of multiple genetic variations on the function of individual neurons.
Authors of the study focused on schizophrenia-linked gene variations that are known to influence cellular structures such as ion channels and calcium transporters. Any changes to these structures would have an impact on the excitability of individual neurons. Using computational analysis, the investigators were able to predict how alterations in these structures would change the behavior of neuronal cells.
"Our computational simulations suggest that mutations in many of the schizophrenia-linked genes affect specific aspects of neuronal excitability and synaptic integration at the single-cell level," explained Dr. Anders Dale, corresponding author of the study and Professor of Neurosciences and Radiology at University of California, San Diego. "The results may provide important clues about basic physiological mechanisms underlying schizophrenia, which could be targeted with pharmaceutical interventions, and also lead to more targeted biomarkers for assessing therapeutic effects."
The published results suggest that most of the studied gene variants could have significant effects on a neuron's behavior. These neuronal changes could be a fundamental contributor to schizophrenia and other psychiatric disorders.
In addition to schizophrenia, this new computational model could be applied to other conditions including bipolar disorder, autism, attention-deficit/hyperactivity disorder, and substance use and addiction, as risk genes related to neuronal excitability in those conditions are identified.
"This novel approach integrates biological and mathematical modeling in the brain to help us understand the link between genetic risk and altered brain function," said Dr. Cameron Carter, Professor of Psychiatry and Behavioral Sciences at University of California, Davis and Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. "Understanding the effect that disease-related genetic variation has on cells could unlock new insights into how to diagnose and treat these disorders."
The article is 'Functional Effects of Schizophrenia-Linked Genetic Variants on Intrinsic Single-Neuron Excitability: A Modeling Study' by Tuomo Mäki-Marttunen, Geir Halnes, Anna Devor, Aree Witoelar, Francesco Bettella, Srdjan Djurovic, Yunpeng Wang, Gaute T.Einevoll, Ole A. Andreassen, and Anders M. Dale (doi: 10.1016/j.bpsc.2015.09.002). The article appears in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Volume 1, Issue 1 (January 2016), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at 1-214-648-0880 or [email protected] Journalists wishing to interview the authors may contact Dr. Anders Dale at [email protected]
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
Cameron S. Carter, M.D., is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
p>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. http://www.elsevier.com